FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3040741566> ?p ?o ?g. }

• W3040741566 abstract "Abstract Background Cardiac sequelae of past SARS-CoV-2 infection are still poorly documented. We conducted a cross-sectional study in health-care workers to report evidence of pericarditis and myocarditis after SARS-CoV-2 infection. Methods We studied 139 health-care workers with confirmed past SARS-CoV-2 infection (103 diagnosed by RT-PCR and 36 by serology). Participants underwent clinical assessment, electrocardiography, laboratory tests including immune cell profiling and cardiac magnetic resonance (CMR). Pericarditis was diagnosed when classical criteria were present, and the diagnosis of myocarditis was based on the updated CMR Lake-Louise-Criteria. Results Median age was 52 years (IQR 41–57), 100 (72%) were women, and 23 (16%) were previously hospitalized for Covid-19 pneumonia. At examination (10.4 [9.3–11.0] weeks after infection-like symptoms), all participants presented hemodynamic stability. Chest pain, dyspnoea or palpitations were observed in 58 (42%) participants; electrocardiographic abnormalities in 69 (50%); NT-pro-BNP was elevated in 11 (8%); troponin in 1 (1%); and CMR abnormalities in 104 (75%). Isolated pericarditis was diagnosed in 4 (3%) participants, myopericarditis in 15 (11%) and isolated myocarditis in 36 (26%). Participants diagnosed by RT-PCR were more likely to still present symptoms than participants diagnosed by serology (73 [71%] vs 18 [50%]; p=0.027); nonetheless, the prevalence of pericarditis or myocarditis was high in both groups (44 [43%] vs 11 [31%]; p=0.238). Most participants (101 [73%]) showed altered immune cell counts in blood, particularly decreased eosinophil (37 [27%]; p<0.001) and increased CD4 - CD8 -/lo Tαβ-cell numbers (24 [17%]; p<0.001). Pericarditis was associated with elevated CD4 - CD8 -/lo Tαβ-cell numbers (p=0.011), while participants diagnosed with myopericarditis or myocarditis had lower (p<0.05) plasmacytoid dendritic cell, NK-cell and plasma cell counts and lower anti-SARS-CoV-2-IgG antibody levels (p=0.027). Conclusions Pericarditis and myocarditis with clinical stability are frequent long after SARS-CoV-2 infection, even in presently asymptomatic subjects. These observations will probably apply to the general population infected and may indicate that cardiac sequelae might occur late in association with an altered (delayed) innate and adaptative immune response. The trial is registered with ClinicalTrials.gov, number NCT04413071 Research in context Evidence before this study Very little evidence exists describing long cardiac sequelae after SARS-CoV-2 infection. Although pericarditis and myocarditis are the two most frequent cardiac manifestations observed after a viral infection, as of May 13, 2020, the peer-reviewed literature was limited to isolated case reports of myocarditis and pericarditis during the COVID-19 hospitalization phase and to a retrospective observation in 26 recovered patients with COVID-19 pneumonia presenting cardiac complaints during hospitalization, revealing the presence of myocardial oedema in 14 (54%) patients and late gadolinium enhancement in 8 (31%) patients. These small size case series, limited to hospitalized RT-PCR patients with COVID-19 pneumonia, are insufficient to generalize conclusions about the true prevalence of pericardial and myocardial long involvement after SARS-CoV-2 infection. In addition, no study has investigated the immunological consequences of SARS-CoV-2 infection in the settings of pericarditis and myocarditis. Added value of this study To our knowledge, this is the largest cohort of subjects (N=139) —even for other common viruses— with clinical, electrocardiographic, laboratory and CMR imaging evaluations, to assess pericardial and myocardial involvements after SARS-CoV-2 infection. The strength of this study is the addition of non-hospitalized participants and also the inclusion of participants diagnosed of past SARS-CoV-2 infection through serology. Contrary to previous studies, women are well represented. We found a prevalence of pericarditis or myocarditis up to 40% cases; pericarditis coexisted with some degree of concurrent myocardial inflammation in 11% cases. Study participants who were previously hospitalized for COVID-19 pneumonia and patients who received antiviral (hydroxychloroquine, lopinavir-ritonavir) or anti-inflammatory (high-dose glucocorticoids and anti-interleukin treatments) treatments, and who were on chronic drug treatment with statins, were less likely to develop pericarditis or myocarditis. The clinical assessment of the participants showed clinical stability without any patient presenting severe pericardial effusion, heart failure or left ventricular dysfunction. We provide new data on seropositive subjects; although RT-PCR participants were more likely to still present symptoms than participants diagnosed by serology, the prevalence of pericarditis, myocarditis or myocarditis, almost three months after the initial viral prodrome, was high in both groups. In-depth investigation of the distribution of multiple major and minor populations of immune cells in blood showed high frequency of altered immune profiles after SARS-CoV-2 infection. The altered immune cell profiles identified partially mimic abnormalities previously reported during active infection together with others described here for the first time, with unique patterns associated with pericardial and/or myocardial injury. Nonetheless, we also described altered immune profiles in participants without pericardial and myocardial manifestations. Whether these later alterations are due to persistence of tissue damage in other organs affected by SARS-CoV-2, such as the lung, or they reflect normal post-infection immune recovery mechanisms, remains to be investigated. Implications of all the available evidence At present, there is much interest in the long-term sequelae of COVID-19. It is intriguing that pericarditis and myocarditis were observed so long after SARS-CoV-2 infection and also in some presently asymptomatic subjects, in association with notably altered immune cell profiles in blood. These observations will probably apply to the general population infected and may indicate that cardiac sequelae might occur late, paving the way for a better understanding the immune mechanisms involved. Thus, our study may have health-care consequences given the widespread diagnosis of SARS-CoV-2 infection in population-based seroprevalence studies." @default.
• W3040741566 created "2020-07-16" @default.
• W3040741566 creator A5004414746 @default.
• W3040741566 creator A5007278221 @default.
• W3040741566 creator A5014213675 @default.
• W3040741566 creator A5017326983 @default.
• W3040741566 creator A5017420618 @default.
• W3040741566 creator A5028461122 @default.
• W3040741566 creator A5029630155 @default.
• W3040741566 creator A5030136239 @default.
• W3040741566 creator A5034650743 @default.
• W3040741566 creator A5045301710 @default.
• W3040741566 creator A5049051135 @default.
• W3040741566 creator A5051937379 @default.
• W3040741566 creator A5053251484 @default.
• W3040741566 creator A5056524141 @default.
• W3040741566 creator A5062943407 @default.
• W3040741566 creator A5073483998 @default.
• W3040741566 creator A5073762441 @default.
• W3040741566 creator A5078773356 @default.
• W3040741566 creator A5080859060 @default.
• W3040741566 creator A5082100643 @default.
• W3040741566 creator A5088292706 @default.
• W3040741566 date "2020-07-14" @default.
• W3040741566 modified "2023-10-17" @default.
• W3040741566 title "Pericarditis and myocarditis long after SARS-CoV-2 infection: a cross-sectional descriptive study in health-care workers" @default.
• W3040741566 cites W2090630520 @default.
• W3040741566 cites W2119169318 @default.
• W3040741566 cites W2126824733 @default.
• W3040741566 cites W2132401137 @default.
• W3040741566 cites W2195401421 @default.
• W3040741566 cites W2736642640 @default.
• W3040741566 cites W2903759577 @default.
• W3040741566 cites W2913298021 @default.
• W3040741566 cites W2937654605 @default.
• W3040741566 cites W2969224238 @default.
• W3040741566 cites W2998391591 @default.
• W3040741566 cites W3009030444 @default.
• W3040741566 cites W3009859788 @default.
• W3040741566 cites W3009912996 @default.
• W3040741566 cites W3011758246 @default.
• W3040741566 cites W3016489853 @default.
• W3040741566 cites W3022275710 @default.
• W3040741566 cites W3022580747 @default.
• W3040741566 cites W3022878099 @default.
• W3040741566 cites W3023125802 @default.
• W3040741566 cites W3023206311 @default.
• W3040741566 cites W3023630330 @default.
• W3040741566 cites W3025099228 @default.
• W3040741566 cites W3028583791 @default.
• W3040741566 cites W3033054596 @default.
• W3040741566 cites W3035189381 @default.
• W3040741566 cites W4240413437 @default.
• W3040741566 doi "https://doi.org/10.1101/2020.07.12.20151316" @default.
• W3040741566 hasPublicationYear "2020" @default.
• W3040741566 type Work @default.
• W3040741566 sameAs 3040741566 @default.
• W3040741566 citedByCount "25" @default.
• W3040741566 countsByYear W30407415662020 @default.
• W3040741566 countsByYear W30407415662021 @default.
• W3040741566 countsByYear W30407415662022 @default.
• W3040741566 countsByYear W30407415662023 @default.
• W3040741566 crossrefType "posted-content" @default.
• W3040741566 hasAuthorship W3040741566A5004414746 @default.
• W3040741566 hasAuthorship W3040741566A5007278221 @default.
• W3040741566 hasAuthorship W3040741566A5014213675 @default.
• W3040741566 hasAuthorship W3040741566A5017326983 @default.
• W3040741566 hasAuthorship W3040741566A5017420618 @default.
• W3040741566 hasAuthorship W3040741566A5028461122 @default.
• W3040741566 hasAuthorship W3040741566A5029630155 @default.
• W3040741566 hasAuthorship W3040741566A5030136239 @default.
• W3040741566 hasAuthorship W3040741566A5034650743 @default.
• W3040741566 hasAuthorship W3040741566A5045301710 @default.
• W3040741566 hasAuthorship W3040741566A5049051135 @default.
• W3040741566 hasAuthorship W3040741566A5051937379 @default.
• W3040741566 hasAuthorship W3040741566A5053251484 @default.
• W3040741566 hasAuthorship W3040741566A5056524141 @default.
• W3040741566 hasAuthorship W3040741566A5062943407 @default.
• W3040741566 hasAuthorship W3040741566A5073483998 @default.
• W3040741566 hasAuthorship W3040741566A5073762441 @default.
• W3040741566 hasAuthorship W3040741566A5078773356 @default.
• W3040741566 hasAuthorship W3040741566A5080859060 @default.
• W3040741566 hasAuthorship W3040741566A5082100643 @default.
• W3040741566 hasAuthorship W3040741566A5088292706 @default.
• W3040741566 hasBestOaLocation W30407415661 @default.
• W3040741566 hasConcept C126322002 @default.
• W3040741566 hasConcept C142052008 @default.
• W3040741566 hasConcept C142724271 @default.
• W3040741566 hasConcept C159654299 @default.
• W3040741566 hasConcept C164705383 @default.
• W3040741566 hasConcept C203014093 @default.
• W3040741566 hasConcept C2776403943 @default.
• W3040741566 hasConcept C2777914695 @default.
• W3040741566 hasConcept C2778704086 @default.
• W3040741566 hasConcept C2780875844 @default.
• W3040741566 hasConcept C2781001862 @default.
• W3040741566 hasConcept C2781175549 @default.
• W3040741566 hasConcept C2781205601 @default.
• W3040741566 hasConcept C45189115 @default.
• W3040741566 hasConcept C71924100 @default.

• next